Johnson & Johnson's multiple myeloma drug reduces risk of death in late-stage study

Johnson & Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday.

from Reuters: Health https://ift.tt/2zEnjbm
via IFTTT

• Tweet
• Share
• Share
• Share
• Share